Clinical trial · Interventional
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
UARK, 98-032, Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
NCT00083694CI-TRIAL-00003627completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thalidomide | Drug | Thalidomide | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the efficacy and safety of Thalidomide in patients with leukemia.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of refractory or relapsed leukemia: acute leukemia, CML, CLLm and MDS. * Signed informed consent, including patient agreeing to use safe contraceptive methods during the treatment and for at least 4 months after the treatment is completed * Serum creatinine \< or = 2.5mg/dL * Serum bilirubin\< or = 2.5mg/dL * Negative pregnancy test * Age 18 years or older * Performance status \< or = 3 Exclusion Criteria: * Pregnant or lactating women * Concurrent treatment with cytotoxic chemotherapy, or radiation * History of seizures, neurotoxicity, or active CNS disease * Serious infections not controlled by antibiotics
References
Publications (0)
Data not yet available
No reference posted for this study.